279 related articles for article (PubMed ID: 14648103)
1. Genetic polymorphisms and prostate cancer risk.
Gsur A; Feik E; Madersbacher S
World J Urol; 2004 Feb; 21(6):414-23. PubMed ID: 14648103
[TBL] [Abstract][Full Text] [Related]
2. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
[TBL] [Abstract][Full Text] [Related]
3. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
[TBL] [Abstract][Full Text] [Related]
4. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
5. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
7. [Polymorphisms of hormone-related genes and prostate cancer risk in Japan].
Watanabe M; Hirokawa Y; Shiraishi T
Nihon Rinsho; 2005 Feb; 63(2):219-24. PubMed ID: 15714969
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
9. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
[TBL] [Abstract][Full Text] [Related]
10. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
12. Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.
Larré S; Hamadeh H; Azzouzi AR; Vallancien G; Cochand-Priollet B; Cancel-Tassin G; Cussenot O
BJU Int; 2007 Sep; 100(3):679-84. PubMed ID: 17669147
[TBL] [Abstract][Full Text] [Related]
13. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
[TBL] [Abstract][Full Text] [Related]
14. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population.
Sobti RC; Gupta L; Singh SK; Seth A; Kaur P; Thakur H
Cancer Genet Cytogenet; 2008 Sep; 185(2):78-85. PubMed ID: 18722876
[TBL] [Abstract][Full Text] [Related]
15. Genetic variations in the vitamin D receptor, androgen receptor and enzymes that regulate androgen metabolism.
Price DK; Franks ME; Figg WD
J Urol; 2004 Feb; 171(2 Pt 2):S45-9; discussion S49. PubMed ID: 14713753
[TBL] [Abstract][Full Text] [Related]
16. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population.
Okugi H; Nakazato H; Matsui H; Ohtake N; Nakata S; Suzuki K
Cancer Detect Prev; 2006; 30(3):262-8. PubMed ID: 16859836
[TBL] [Abstract][Full Text] [Related]
17. Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men.
Izmirli M; Arikan B; Bayazit Y; Alptekin D
Asian Pac J Cancer Prev; 2011; 12(3):731-3. PubMed ID: 21627373
[TBL] [Abstract][Full Text] [Related]
18. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy.
dos Santos RM; de Jesus CM; Trindade Filho JC; Trindade JC; de Camargo JL; Rainho CA; Rogatto SR
DNA Cell Biol; 2008 Sep; 27(9):497-503. PubMed ID: 18491956
[TBL] [Abstract][Full Text] [Related]
19. Inherited variation in hormone-regulating genes and prostate cancer survival.
Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F
Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
Rossi L; Leveri M; Gritti C; De Silvestri A; Zavaglia C; Sonzogni L; Silvestri L; Civardi E; Mondelli MU; Silini EM
J Hepatol; 2003 Oct; 39(4):564-70. PubMed ID: 12971967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
